PACB
Price
$1.85
Change
-$0.11 (-5.58%)
Updated
Dec 18, 04:59 PM (EDT)
57 days until earnings call
SKHHY
Price
$17.87
Change
+$0.18 (+1.02%)
Updated
Dec 17 closing price
63 days until earnings call
Ad is loading...

PACB vs SKHHY

Header iconPACB vs SKHHY Comparison
Open Charts PACB vs SKHHYBanner chart's image
Pacific Biosciences of California
Price$1.85
Change-$0.11 (-5.58%)
Volume$361.84K
CapitalizationN/A
Sonic Healthcare
Price$17.87
Change+$0.18 (+1.02%)
Volume$42.83K
CapitalizationN/A
PACB vs SKHHY Comparison Chart
Loading...
PACB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SKHHY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
PACB vs. SKHHY commentary
Dec 19, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PACB is a Hold and SKHHY is a Hold.

COMPARISON
Comparison
Dec 19, 2024
Stock price -- (PACB: $1.97 vs. SKHHY: $17.87)
Brand notoriety: PACB and SKHHY are both not notable
Both companies represent the Medical Specialties industry
Current volume relative to the 65-day Moving Average: PACB: 60% vs. SKHHY: 121%
Market capitalization -- PACB: $976.68M vs. SKHHY: $11.02B
PACB [@Medical Specialties] is valued at $976.68M. SKHHY’s [@Medical Specialties] market capitalization is $11.02B. The market cap for tickers in the [@Medical Specialties] industry ranges from $3.82T to $0. The average market capitalization across the [@Medical Specialties] industry is $8.04B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

PACB’s FA Score shows that 0 FA rating(s) are green whileSKHHY’s FA Score has 1 green FA rating(s).

  • PACB’s FA Score: 0 green, 5 red.
  • SKHHY’s FA Score: 1 green, 4 red.
According to our system of comparison, SKHHY is a better buy in the long-term than PACB.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

PACB’s TA Score shows that 6 TA indicator(s) are bullish while SKHHY’s TA Score has 5 bullish TA indicator(s).

  • PACB’s TA Score: 6 bullish, 3 bearish.
  • SKHHY’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, PACB is a better buy in the short-term than SKHHY.

Price Growth

PACB (@Medical Specialties) experienced а -15.81% price change this week, while SKHHY (@Medical Specialties) price change was -2.14% for the same time period.

The average weekly price growth across all stocks in the @Medical Specialties industry was -4.17%. For the same industry, the average monthly price growth was +1.60%, and the average quarterly price growth was -0.66%.

Reported Earning Dates

PACB is expected to report earnings on Feb 13, 2025.

SKHHY is expected to report earnings on Feb 19, 2025.

Industries' Descriptions

@Medical Specialties (-4.17% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SKHHY($11B) has a higher market cap than PACB($977M). SKHHY YTD gains are higher at: -12.576 vs. PACB (-79.918). SKHHY has higher annual earnings (EBITDA): 2.19B vs. PACB (-277.28M). SKHHY has higher revenues than PACB: SKHHY (8.65B) vs PACB (201M).
PACBSKHHYPACB / SKHHY
Capitalization977M11B9%
EBITDA-277.28M2.19B-13%
Gain YTD-79.918-12.576635%
P/E RatioN/A16.45-
Revenue201M8.65B2%
Total Cash631MN/A-
Total Debt934MN/A-
FUNDAMENTALS RATINGS
PACB vs SKHHY: Fundamental Ratings
PACB
SKHHY
OUTLOOK RATING
1..100
7468
VALUATION
overvalued / fair valued / undervalued
1..100
99
Overvalued
3
Undervalued
PROFIT vs RISK RATING
1..100
10091
SMR RATING
1..100
9893
PRICE GROWTH RATING
1..100
4654
P/E GROWTH RATING
1..100
8262
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SKHHY's Valuation (3) in the null industry is significantly better than the same rating for PACB (99) in the Biotechnology industry. This means that SKHHY’s stock grew significantly faster than PACB’s over the last 12 months.

SKHHY's Profit vs Risk Rating (91) in the null industry is in the same range as PACB (100) in the Biotechnology industry. This means that SKHHY’s stock grew similarly to PACB’s over the last 12 months.

SKHHY's SMR Rating (93) in the null industry is in the same range as PACB (98) in the Biotechnology industry. This means that SKHHY’s stock grew similarly to PACB’s over the last 12 months.

PACB's Price Growth Rating (46) in the Biotechnology industry is in the same range as SKHHY (54) in the null industry. This means that PACB’s stock grew similarly to SKHHY’s over the last 12 months.

SKHHY's P/E Growth Rating (62) in the null industry is in the same range as PACB (82) in the Biotechnology industry. This means that SKHHY’s stock grew similarly to PACB’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
PACBSKHHY
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
89%
Bullish Trend 2 days ago
69%
Momentum
ODDS (%)
Bullish Trend 2 days ago
82%
Bearish Trend 2 days ago
66%
MACD
ODDS (%)
Bullish Trend 2 days ago
81%
Bearish Trend 2 days ago
65%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
68%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
86%
Bullish Trend 2 days ago
67%
Advances
ODDS (%)
Bullish Trend 9 days ago
84%
Bullish Trend 2 days ago
68%
Declines
ODDS (%)
Bearish Trend 6 days ago
88%
Bearish Trend 6 days ago
69%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
74%
Aroon
ODDS (%)
Bullish Trend 2 days ago
89%
Bullish Trend 2 days ago
60%
View a ticker or compare two or three
Ad is loading...
PACB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SKHHY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
AOPCX29.33N/A
N/A
Virtus International S/C C
BLDIX9.46-0.02
-0.21%
BlackRock Managed Income Institutional
MIGBX36.42-0.12
-0.33%
MFS Massachusetts Inv Gr Stk B
NMULX10.58-0.07
-0.66%
Neuberger Berman Multi-Cap Opp I
FZAOX38.02-0.54
-1.40%
Fidelity Advisor Small Cap Z

PACB and

Correlation & Price change

A.I.dvisor indicates that over the last year, PACB has been loosely correlated with MASI. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if PACB jumps, then MASI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PACB
1D Price
Change %
PACB100%
-3.90%
MASI - PACB
58%
Loosely correlated
-1.80%
AZTA - PACB
47%
Loosely correlated
+4.09%
MASS - PACB
44%
Loosely correlated
-5.58%
RVTY - PACB
43%
Loosely correlated
-0.36%
TWST - PACB
41%
Loosely correlated
-0.06%
More

SKHHY and

Correlation & Price change

A.I.dvisor tells us that SKHHY and CHEOY have been poorly correlated (+28% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that SKHHY and CHEOY's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SKHHY
1D Price
Change %
SKHHY100%
+1.02%
CHEOY - SKHHY
28%
Poorly correlated
+2.50%
ILMN - SKHHY
27%
Poorly correlated
-0.89%
SAUHY - SKHHY
26%
Poorly correlated
-0.08%
PACB - SKHHY
24%
Poorly correlated
-3.90%
LAB - SKHHY
23%
Poorly correlated
+3.27%
More